Development and current status of Antibody-drug conjugate (ADC)

研究成果: Article査読

抄録

Antibody-drug conjugates (ADCs) are expected as next therapeutic antibodies. At present, four ADCs have been approved. ADCs consist from three components, antibody, cytotoxic agents, and linker. In this paper, recent advances of ADC developments are described. From view of antibody development, internarization ability and cancer stromal targeting therapy concept are described. For cytotoxic agents, features of representative agents including radio isotopes are described. Linker technology development for homogeneous ADC preparation is also focused. Representative bioorthogonal reaction for ADC preparation is also included.

本文言語English
ページ(範囲)10-21
ページ数12
ジャーナルDrug Delivery System
34
1
DOI
出版ステータスPublished - 2019 1月 1
外部発表はい

ASJC Scopus subject areas

  • 薬科学

フィンガープリント

「Development and current status of Antibody-drug conjugate (ADC)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル